Navigation Links
Kendle Announces New Revolving Credit Facility
Date:3/17/2010

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.

Forward-Looking Statements

Certain statements and information contained in this press release may be deemed to be forward-looking statements under federal securities laws and the provisions of the Private Securities Litigation Reform Act of 1995 and Kendle intends that such forward-looking statements be subject to the safe-harbor created thereby. All such forward-looking statements, including the statements contained herein regarding anticipated benefits of the new revolving credit facility, are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those risks as detailed from time to time in Kendle's Annual Report on Form 10-K as well as periodic reports filed with the SEC.  All information in this press release is current as of March 17, 2010. The Company undertakes no duty to update any forward-looking statement to conform the s
'/>"/>

SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast
2. Kendle to Present at UBS Global Life Sciences Conference
3. Kendle to Present at Robert Baird 2009 Health Care Conference
4. Kendle Realigns C-Suite Leadership to Drive Increased Innovation, Productivity and Organizational Efficiency
5. Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
6. Kendle Names Jarrod Pontius Chief Legal Officer
7. Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
8. Kendle Announces First Quarter 2009 Results
9. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
10. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
11. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MINNEAPOLIS , Jan. 15, 2014 ­ RedBrick ... and behavior change technology, today announces that EmblemHealth ... insurer and wellness company, is now providing the RedBrick ... digital coaching program, to all of its members. EmblemHealth ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... Reportlinker.com announces that a new market research report ... Global Biotechnology Reagents Industry ... the worldwide markets for Biotechnology Reagents in US$ ... Reagents, DNA Sequencing/Synthesis Reagents, Electrophoresis Reagents, Flow Cytometry ...
... licensed within the next 4 years, as manufacturers are ... candidates in collaboration with health authorities and developing countries ... licensure, a team of leading scientists said. ... for regulatory review of dengue vaccines, while plans are ...
... from the University at Buffalo could lead to new solutions ... from drinking water. To the naked eye, both water ... are measured by the nanometer, a unit of length about ... , But at the microscopic level, the two actually differ ...
Cached Biology Technology:Reportlinker Adds Global Biotechnology Reagents Industry 2Capacity of developing country NRAs key to accelerated introduction of upcoming dengue vaccines 2Capacity of developing country NRAs key to accelerated introduction of upcoming dengue vaccines 3A nano-solution to global water problem: Nanomembranes could filter bacteria 2
(Date:7/10/2014)... ant Anoplolepis gracilipes is ranked amongst the top ... ecological impacts on islands. A new study published in the ... assesses the effects and dangers of the introduction of the ... palm forest of the Valle de Mai, a UNESCO World ... Valle de Mai is a unique ecosystem containing many endemic ...
(Date:7/9/2014)... Philadelphia, PA, July 10, 2014 Inflammatory diseases ... same patient, complicating treatment because a medication effective ... such example is the anti-arthritic medication dexamethasone, which ... disease. A study in the August issue of ... the effects of a new class of anti-arthritic ...
(Date:7/9/2014)... Bacteria found in the bladders of healthy women ... form of incontinence, according to researchers from Loyola ... These findings, published July 9, 2014, in the ... , suggest that bacterial communities may play a ... incontinence (UUI) is a common, yet poorly understood, ...
Breaking Biology News(10 mins):Invasion of yellow crazy ant in a Seychelles UNESCO palm forest: Threats and solutions 2New class of anti-arthritis drugs effectively treats multiple inflammatory diseases 2
... know - are drawing up gold particles from the earth via ... from CSIRO made the discovery and have published their findings in ... a hydraulic pump its roots extend tens of metres into ... gold is likely to be toxic to the plant, it,s moved ...
... , Oct. 23, 2013 Increasing awareness ... commercial biometrics market. While historically the adoption of ... recent years have witnessed considerable demand for applications ... finance. Iris and face recognition algorithms have undergone ...
... SALT LAKE CITYFor people with a family history of ... to 10 percent of colorectal cancers could be missed ... is the third most common cancer in the United ... population-based study to date, researchers from Huntsman Cancer Institute ...
Cached Biology News:There's gold in them thar trees 2Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 2Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 3Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 4Colon cancer screening guidelines may miss 10 percent of colon cancers 2
...
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
Biology Products: